Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.) - A prospective, randomized, double-blind multicenter study

Paolo Pederzoli, Giorgio Cavallini, Massimo Falconi, Claudio Bassi

Research output: Contribution to journalArticlepeer-review

Abstract

The authors report the results of a randomized, double-blind multicenter clinical trial on the use of gabexate mesilate vs aprotinin in the therapy of acute pancreatitis. The size of the study sample and the end points chosen for evaluation of the early systemic complications of the pancreatitis-carefully selected targets for reliable assessment of the efficacy of any protease inhibitor-lead to the conclusion that gabexate mesilate is more efficacious than aprotinin in reducing the early complications of necrotizing acute pancreatitis, if administered within 72 h of onset of symptoms. Its good tolerability means that it can be used safely even at the dose of 3 g/24 h.

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalInternational Journal of Pancreatology
Volume14
Issue number2
DOIs
Publication statusPublished - Oct 1993

Keywords

  • Acute pancreatitis
  • aprotinin
  • gabexate mesilate

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Endocrinology

Fingerprint Dive into the research topics of 'Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.) - A prospective, randomized, double-blind multicenter study'. Together they form a unique fingerprint.

Cite this